1. LBRX included in Russell 2000 and 3000 indices effective December 22, 2025. 2. CEO asserts this milestone aims to broaden investor awareness. 3. Key clinical trials for LB-102 in schizophrenia and bipolar depression are upcoming. 4. Approximately $10.6 trillion benchmarks against the Russell US indices. 5. LB-102 positioned as a potential first-line treatment in psychiatry.
FAQ
Why Bullish?
Inclusion in major indices typically increases visibility and investor confidence, as seen historically with companies like recent IPOs that benefited from similar index additions.
How important is it?
LBRX's increasing recognition and pending clinical trials create a favorable outlook for potential investment and growth.
Why Short Term?
The immediate impact will likely be seen around the index inclusion date and during trial initiations, which can affect stock pricing positively due to heightened investor interest.
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
- Source: LB Pharmaceuticals Inc
LB Pharmaceuticals Inc (Nasdaq: LBRX) has announced its inclusion in the prestigious Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025. This milestone follows the Company’s recent initial public offering and marks a significant step in its corporate journey.
Implications of Inclusion in Major Indices
Heather Turner, Chief Executive Officer of LB Pharmaceuticals, expressed that this inclusion serves as a crucial development in raising investor awareness. She stated, “Inclusion in the Russell 2000 and Russell 3000 indices represents an important milestone following our recent initial public offering. We are approaching initiation of key clinical trials of LB-102 in both schizophrenia and bipolar depression, a period of significant momentum for the Company. We expect this recognition to broaden investor awareness of LB Pharmaceuticals.”
Understanding the Russell Indexes
The annual reconstitution of the Russell US indexes ranks the 4,000 largest US stocks based on total market capitalization as of April 30. Membership in the Russell 3000® Index, which lasts for one year, ensures automatic inclusion in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with their corresponding growth and value style indexes.
- Approximately **$10.6 trillion** in assets are benchmarked against the Russell US indexes.
- FTSE Russell, the global index provider, oversees the memberships, ensuring that they reflect objective market-capitalization rankings and style attributes.
Profile of LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical firm dedicated to developing novel therapies aimed at treating neuropsychiatric conditions, including schizophrenia and bipolar depression. The Company's lead product candidate, **LB-102**, stands poised to potentially become the first benzamide antipsychotic drug approved in the U.S. for such disorders. If successful, LB-102 could offer a compelling new alternative to existing treatments.
Forward-Looking Statements
This announcement includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Keywords such as “anticipate,” “expect,” and “potential” could reflect future intentions and expectations regarding LB Pharmaceuticals and its product, LB-102. However, actual outcomes may differ due to various risks and uncertainties.
Contact Information
For further details, interested parties can contact:
- Media: Michael Tattory, LifeSci Communications, Mtattory@lifescicomms.com
- Investor Relations: Joyce Allaire, LifeSci Advisors, JAllaire@LifeSciAdvisors.com